GETNE Registration of Thyroid Cancer

Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03765333

Enrollment

Registered

2018-12-05

Start date

2019-05-28

Completion date

2025-12-31

Last updated

2024-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Cancer

Brief summary

An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.

Interventions

None listed

Study design

Observational model

ECOLOGIC_OR_COMMUNITY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients older than 18 years with diagnosis of differentiated, medullary or anaplastic thyroid cancer confirmed by histopathology. * Patients who agree to participate and are able to understand the information sheet and sign the informed consent

Exclusion criteria

* Patients under 18 years of age. * Patients with other types of thyroid cancer or whose histopathological diagnosis has not been confirmed. * Patients who do not have the relevant basic information to be included in the study, according to the criteria of the principal investigator.

Design outcomes

Primary

Measure	Time frame	Description
Hystopathological characteristics of the tumor	Baseline	Based on pathologist evaluation of biopsy including differentiated, medullar or anaplasic.
Situation of the tumor at first-diagnosis	Baseline	Local tumor, locoregional tumor or metastatic disease.
Tumor-Node-Metastasis classification	Baseline	Based on the AJCC (American Joint Committee on Cancer) 2018 TNM system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
Tumor Stage	Baseline	From I to IV, based on the interpretation of the TNM classification and depending on the hystopathological characteristics of the tumor.

Secondary

Measure	Time frame	Description
Number of patients with RAS mutation	12 months	Total patients with available results on RAS status and proportion of patients with mutated RAS or native RAS.
Number of patients with PAX8/PAR mutation	12 months	Total patients with available results on PAX8/PAR status and proportion of patients with mutated PAX8/PAR or native PAX8/PAR.
Patient situation at the end of treatment	12 months	Results of clinical evaluation of the disease including complete response, partial response, stable disease, progression of disease or death
Number of patients with PTEN mutation	12 months	Total patients with available results on PTEN status and proportion of patients with mutated PTEN or native PTEN.
Number of patients with P53 mutation	12 months	Total patients with available results on P53 status and proportion of patients with mutated P53 or native P53.
Number of patients with BRAF mutation	12 months	Total patients with available results on BRAF status and proportion of patients with mutated BRAF or native BRAF.
Number of patients with RET mutation	12 months	Total patients with available results on RET status and proportion of patients with mutated RET or native RET.
Number of patients with PI3K mutation	12 months	Total patients with available results on PI3K status and proportion of patients with mutated PI3K or native PI3K.

Countries

Spain

Contacts

Primary ContactSecretaria Técnica GETNE

getne@mfar.net+34 93 434 44 12

Outcome results